Ofatumumab is first self-administered, targeted B-cell treatment for relapsing MS. The first self-administered, targeted B-cell treatment for relapsing multiple sclerosis (MS) received FDA approval

Kategoriler: Kök Hücre tedavisi

NBScience

sözleşmeli araştırma organizasyonu